|
1. Biologie
|
|
|
Understanding Premalignancy and Cancer Risk [Cancer research Catalyst]
|
|
|
|
|
|
To
help decode cancer before it starts, some researchers suggest the need
for an initiative as large as The Cancer Genome Atlas (TCGA), which
provided a map of key genomic changes in 33 types of cancer. Efforts to
study premalignancy, however, would call for far more coordination than
the TCGA needed, since it would require not only analyzing tissue
samples, but also understanding outside factors such as immune system
function.
|
|
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Final NICE nod for Takeda’s Adcetris in Hodgkin’s lymphoma [PharmaTimes]
|
|
|
|
|
|
Final
guidance published by the cost regulator says Adcetris (brentuximab
vedotin) can be considered an option to treat CD30‑positive Hodgkin
lymphoma in adults, but only if they have relapsed or refractory disease
after autologous stem cell transplant and the company provides the drug
at the price agreed with NHS England in the commercial access
agreement.
|
|
|
|
|
|
|
|
'Monumental U-turn' on cancer drug [BBC News]
|
|
|
|
|
|
It
is the result of a confidential deal between the health service and the
drug company Roche. Kadcyla, the undiscounted cost of which had been
£90,000 per patient, adds an average of six months of life to women with
a form of terminal breast cancer.
|
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
Cancer's Big Infrastructure Problem [Forbes]
|
|
|
|
|
|
This
is not a new problem. In 2011, the oncologist George Sledge, then the
outgoing president of ASCO, gave a talk in which he talked about the
need to create an infrastructure to make targeted cancer drugs
tractable. That infrastructure still does not exist, despite all the
talk of cancer moonshots.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
Rebranded UK charity to stream £500m into medical research [PharmaTimes]
|
|
|
|
|
|
The
charity, which evolved from the Medical Research Council, plans to
build on its collaboration model by setting up ‘Communities for Impact’,
networks that will will bring together the partners best placed to
drive forward medical innovation in specific therapeutic and diagnostic
areas.
|
|
|
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.6 Publications
|
|
|
|
6.7.2 Applis
|
|
|